Modern medicine stands at the threshold of a therapeutic revolution in liver disease management, driven by groundbreaking insights into the intricate relationship between metabolic dysfunction and hepatic pathology. The transformation from Non-Alcoholic Steatohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH) exemplifies this paradigm shift, fundamentally altering how clinicians approach liver disease in the context of global Read.